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There are few studies into the rate and causes of histopathological false-positive diagnosis of prostate 
cancer. Only two of these, including a previous one from our group, incorporate survival data. In 
addition, in none of the previous studies had immunohistochemistry been originally requested on any 
of the misdiagnosed cases. Diagnostic biopsies (n=1080) and trans-urethral resection of prostate 
specimens (n=314) from 1394 men with clinically localised prostate cancer diagnosed in the UK but 
treated conservatively between 1990 and 2003 were reviewed by a panel of 3 genitourinary 
pathologists. Thirty five cases were excluded for being potentially incomplete. Of the remaining 1359, 
30 (2.2%) were re-assigned to a non-malignant category (26 benign and 4 suspicious for malignancy). 
Immunohistochemistry had been originally performed on 7 of these. The reasons for the errors were 
recorded on each case: adenosis (19), partial atrophy (3), PIN (2), seminal vesicle epithelium (1) and 
hyperplasia (1). Follow-up of these men revealed only one prostate cancer related death, possibly due 
to un-sampled tumour.  In conclusion, a relatively small number of prostate cancer mimics were 
responsible for a large proportion of the false-positive prostate cancer diagnoses and the use of 
immunohistochemistry did not prevent the overcall of benign entities as cancer in approximately a 
quarter of these cases. Targeting these mimics at educational events and raising awareness of the 
pitfalls in the interpretation of immunohistochemistry in prostate cancer diagnosis, emphasising that 
glands within a suspicious focus should be treated as a whole rather than individually, may be 
beneficial in lowering the rate of false-positive diagnosis. 
 





Morphological interpretation of H&E stained slides with the aid of immunohistochemistry (IHC) in 
selected cases remains the gold standard for prostate cancer diagnosis. The increasing incidence of 
prostate cancer has been fuelled by an aging population and opportunistic Prostatic Specific Antigen 
(PSA) screening especially in Western developed countries. Mortality is also rising probably also in 
keeping with an aging population. The vast majority of diagnoses are currently based on needle core 
biopsies of the prostate, performed according to an extended sextant protocol usually taking 12 cores 
1 though template biopsies 2 are increasing. 3,4 This, and the need to re-biopsy men on active 
surveillance, has caused a substantial increase in the number of cores taken per patient and an 
extremely heavy burden of diagnostic material for genitourinary pathologists.  The reduction in 
number of cores per patient and number of patients biopsied anticipated with the implementation of 
targeted biopsies only aiming at areas of the prostate identified as potential cancers on 
multiparametric MRI 5 has not yet materialised in most institutions. 
 The consequences of misdiagnosis of prostate cancer in this modern environment are far reaching for 
individual patients with both psychological and physical harm possible. Systematic study to try and 
elucidate the nature and origin of the errors would be highly beneficial with a view to reduce them. 
However, there have been very few studies into the rate and possible causes of prostate cancer false-
positive diagnosis and none have included cases where IHC had been originally performed. 6, 7, 8, 9, 10 A 
major difficulty in the identification of error includes genuine differences in opinion on borderline 
cases, making surveys without outcome data of dubious value. Only two studies, 6, 8 including one from 
our group, incorporate long term follow-up with death from prostate cancer as an outcome. Our 
previous study was necessarily in a cohort which was predominantly based on trans-urethral resection 
(TURP) specimens and before IHC had become widespread.   
We therefore wished to examine the error rate in a more contemporaneous cohort of conservatively 




Materials and Methods 
This work is based on a cohort originally assembled with the aim to study the natural history of 
prostate cancer. 11 Patients were identified from three cancer registries in Great Britain and 
collaborating hospitals from these regions were contacted with the request to review the cases. The 
inclusion criteria were: men under 76 years old at diagnosis with clinically localised prostate cancer 
diagnosed by biopsy or TURP between 1990 and 2003 inclusively. The median date of diagnosis was 
May 2002. The exclusion criteria were: radical therapy (surgery or radiotherapy) within 6 months of 
diagnosis, hormone therapy before biopsy/TURP, metastatic disease recorded by objective evidence 
(bone scan, X-ray, radiograph, CT scan, MRI, bone biopsy, lymph node biopsy and pelvic lymph node 
dissection) or by clinical indications (pathologic fracture, soft-tissue metastases, spinal compression, 
or bone pain), or by a PSA measurement over 100 ng/ml at or within 6 months of diagnosis, death 
within 6 months of diagnosis and finally, men who had less than 6 months of follow-up. The cohort 
was thus established in a pragmatic manner on the assumption that 6 months was sufficient to allow 
for initial treatment options to be decided. Original paraffin-embedded blocks and/or slides used for 
the primary diagnosis of cancer were requested and centrally reviewed by a panel of three expert 
urological pathologists (GS, DB and LB) to confirm the diagnosis of adenocarcinoma and to reassign a 
Gleason score using a contemporary and consistent interpretation of the Gleason scoring system. The 
panel met and discussed all controversial cases including all the ones where cancer could not be 
confirmed and a selection of others to audit the data set. All unconfirmed cases were excluded from 
the primary study on the natural history of prostate cancer and within these, only those that were 
regarded complete were included in this study, to ensure that the discrepancy was not the result of 
missing material. Immunohistochemistry using CK5/6 (monoclonal; DAKO, Carpinteria, CA), P63 
(monoclonal; DAKO, Carpinteria, CA) and AMACR (monoclonal; DAKO, Carpinteria, CA) was performed 
if needed. A possible cause for any overdiagnosis was identified by consensus between the 
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pathologists and recorded in each discordant case.  Follow-up was conducted through the cancer 
registries and the cut-off date was 31 December 2012. Deaths were divided into those from prostate 
cancer and those from other causes, according to World Health Organisation standardised criteria 
(WHO, 2010). National ethics approval was obtained from the Northern Multicentre Research Ethics 
Committee, followed by local ethics committee approval at each of the collaborating hospitals. 
 
Results 
Out of 1394 cases reviewed consisting of 1080 biopsies (median number of cores=6) and 314 TURPs, 
a diagnosis of prostate cancer could not be confirmed histologically in 65 specimens. However, in 35 
of these, the panel could not be absolutely certain that the material examined was complete, after 
close examination of block and slide numbers, and these were therefore excluded for the purpose of 
this study. Of the remaining 30 specimens comprising 2.2% of the cohort, 26 (19 biopsies and 7 TURPs) 
were re-classified as benign and 4 (all biopsies) were assigned as suspicious for malignancy.  The 
proportion of miss-assigned cases was nearly identical in biopsies (2.1%) and TURPs (2.2%). In five 
cases the area of concern that had led to the erroneous diagnosis of cancer had been marked by the 
reporting pathologist on the slide. 
 The most common error on biopsies was the interpretation of areas of adenosis as cancer (13 of 19 
biopsies), followed by partial atrophy, PIN, seminal vesicle epithelium and crowded glands in the 
context of hyperplasia.  Adenosis, including one case of sclerosing adenosis, was the reason for error 
in 6 of the 7 cases of TURP, whilst no definite reason was noted in one case (Table 1).  
IHC for basal cell markers but not for AMACR, due to the cohort’s age, had originally been performed 
on 7 of the miss-assigned cases. It was performed by ourselves, including AMACR, on another 4. Of 
the 7 cases, 6 contained adenosis and 1 partial atrophy. Basal cell markers demonstrated a 
discontinuous basal cell layer including the occasional gland completely lacking basal cells in 4 cases.  
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On the other 2, the technical quality of the staining precluded any meaningful interpretation.  In the 
case of partial atrophy, IHC did demonstrate a basal layer. Examples of the cases are shown in Figures 
1-5 
Survival data was available for 26 of the 30 discordant cases and their Kaplan-Meier survival curve was 
compared with that of the prostate cancer cases and their different grades. With 10 years follow-up 
there was 1 (4%) death from prostate cancer in the 26 cases, which corresponds to a man who had a 
biopsy triggered by a PSA of 5.6. This death rate was very similar to that of confirmed Gleason 6 cases, 
found to be 5%. The death rate from Gleason 3+4=7 cases was much higher at 13%. 11 
 
Discussion 
The diagnosis of prostate cancer, particularly on biopsies is challenging, as there are many pathological 
mimics of malignancy especially where only a limited amount of tissue is seen. There is also no 
absolute cut off between an atypical small acinar proliferation and malignancy where there is 
inevitably a degree of subjectivity of diagnosis. 12, 13 Studies examining genuine misdiagnosis in 
prostate cancer are therefore contentious. The high frequency of the disease in elderly men with a 
raised PSA and indolent nature of the disease means that false-positive diagnoses will not be 
appreciated in the majority of men who are not treated surgically. Even after radical prostatectomy, 
the high incidence of the disease means that small foci of disease seen at radical prostatectomy may 
not be related to the changes seen at biopsy.  
Therefore, there are very few studies into the rate and causes of prostate cancer false-positive 
diagnosis in histopathology 6, 7, 8, 9, 10 and only two 6, 8 including a previous study by our group, 
incorporate survival data, being the optimal method to demonstrate indolent behaviour. These 
studies were based on specimens dating from a time when IHC had not yet been widely implemented; 
none of the misdiagnosed cases had IHC originally performed. The current study is the largest in terms 
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of biopsies and the only one including IHC, with 23% of the overcalls having this originally performed. 
A comparison with the previous studies is shown in Table 2.  
We have applied very strict criteria to label a case as false-positive by excluding all re-cuts and 
potentially incomplete material, which has led to a high exclusion rate. This approach guarantees that 
the reasons for the false-positive diagnosis recorded are genuine in all cases. However, we are aware 
that the drawback is that the proportion of false-positives found in the study may be an 
underestimate.  Within this conservative approach, the percentage of false positives stands at 2.2%. 
The mortality rate of this group was 4% which is very similar to that of Gleason score 3+3=6 (5%) but 
much lower than that of Gleason score 3+4=7 (13%). 11 
 We suggest that the single death from prostate cancer within the false-positive group was most likely 
due to un-sampled tumour. TRUS biopsy has been found to have a sensitivity of only 48% and a 
negative predictive value of 63% in detecting clinically significant prostate cancer defined as any 
Gleason score  > or = 3+4 recently. 14 Compared with our previous study, 8 there is a much smaller 
difference between the mortality rates in the false-positive cases and the Gleason score 6 cases. This 
is due to the fact that, whilst the mortality in the false-positive group is similar in both studies (6% in 
the previous and 4% in the current), there is a higher mortality of Gleason score 6 cases in the previous 
series (13%). This higher mortality can be explained by a number of factors. Firstly, the original series 
was not based on sextant or decant sampling with the median number of cores being 2, 15 which 
contrasts with a median of 6 cores in the current study. This under-sampling is more likely to result in 
under-grading, meaning that many cases of Gleason 3+3=6 would have had un-sampled areas of 
Gleason pattern 4. Secondly, Gleason grade drift, the consequence of the changes introduced to the 
Gleason scoring system during the last decade may have led to changes in interpretation. Glomeruloid 
and small cribriform glands were generally regarded Gleason pattern 3 when the previous cohort was 
scored.  Gleason grade drift has been well documented 16 and is responsible for the Will Rogers 
phenomenon where any given grade may show better survival over time. 17  
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Several benign mimickers of adenocarcinoma have been described 18, 19, 20 of which adenosis, or 
atypical adenomatous hyperplasia, is the most frequent cause of misdiagnosis in this series (19/30 
cases or 63%). Adenosis is mostly present in the transitional zone and therefore is more commonly 
found in TURP specimens. It consists of a well-defined nodular area of tightly packed small round 
glands which can display some degree cytological atypia. Its non-infiltrative growth pattern cannot be 
appreciated in biopsies, where the lesion is typically not fully represented and therefore its recognition 
is not always straightforward. The basal cell layer is preserved, albeit in a discontinuous fashion focally, 
in all cases. Depending of the plane of section it is not rare to find one or several acini completely 
lacking basal cells within the context of otherwise characteristic morphological features of adenosis. 
18, 21 It was precisely the finding of occasional acini with no basal cells demonstrated on IHC that 
appeared to prompt an erroneous diagnosis of malignancy originally in 4 of the cases of adenosis in 
our series.  
 Adenosis, or less florid forms of glandular crowding, has also been the most common source of 
misdiagnosis in previous studies, including our own despite the studies having major differences with 
regards to the time of original diagnosis, specimen type and clinical context and reasons for review. 6, 
7, 8, 9, 10  The first, by Bostwick et al, 6 performed on 150 cases originally diagnosed between 1960 and 
1970 as low-grade cancer pT1a on TURPs from the Mayo Clinic, found adenosis, including sclerosing 
adenosis, in 11 (35%) of 35 misdiagnosed cases. Adenosis had not even been described at the time of 
the original diagnosis and in fact Gleason patterns 1 and 2 were probably based on this entity in many 
cases. 22 Pathologists were therefore merely following Gleason’s descriptions and drawings when 
diagnosing carcinoma in these cases with no IHC available. On long-term follow up all men with a false-
positive diagnosis where free of prostate cancer. A study by Epstein et al 7 was based on biopsies from 
535 men originally diagnosed during 1993-1994 and reviewed at Johns Hopkins prior to radical 
treatment. This found adenosis in 5 (71%) of 7 misdiagnosed cases, in a proportion similar to the 
current study. No IHC had been performed originally. No follow up was available. Our previous study 
8 contained roughly the same number of biopsies and TURP specimens and was based on a cohort 
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with clinical features identical to the current (men with localised disease conservatively treated during 
the first 6 months), apart from the period of the original diagnosis (1990-1996) when IHC was not 
widely available. Adenosis was the cause of the overcall in 38 (28%) of the 133 misdiagnoses. No 
reason for the discordant diagnosis is specified in the study by Brimo et al. 9  
Contrary to our previous study 8 and that of Bostwick et al  6 no inflammatory conditions were found 
to be the origin of any overcall in the current study.  This may be related to pathologists having a 
higher threshold to diagnose malignancy in the presence of inflammatory changes.  
Herawi et al 23 have looked at benign mimics of prostate cancer from a different perspective. Their 
study is based on 567 biopsies from consultation cases referred for second opinion where the 
contributing pathologist questioned malignancy and the expert review classified as benign. No change 
in diagnosis was made as no firm diagnosis of malignancy was rendered in the first place. Nearly half 
of their cases had IHC originally performed, which is expected as this cohort is by definition formed by 
cases deemed to be difficult. Their findings are similar to ours in that patchy or focally absent staining 
for basal cell markers on IHC in the context of a benign small glandular proliferation raised the 
possibility of malignancy. Their most common findings were partial atrophy (35.8%) and crowded 
small glands (25.7%). The difference with our study is that in theirs, the contributing pathologist 
decided to send the case for expert opinion rather than assigning it to a malignant category. However, 
no follow up was available.  
The issue of false-positive prostate cancer diagnosis has also been examined by Van der Kwast et al, 
10 who have analysed data from two of eight centres involved in the European Randomized study of 
Screening for Prostate Cancer (ERSCP) where all prostate cancer diagnoses performed by general 
pathologists were routinely screened by experienced reference uropathologists based in each of the 
centres. The review appears to have happened prior to participants enrolling on the study and 
therefore it is not clear whether a formal diagnosis of prostate cancer was actually rendered based on 
any of the re-labelled biopsies. Out of a total of 1950 cases screened, they found 7 (0.36%) where the 
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diagnosis of prostate cancer was reversed. The most common cause of error was post-atrophic 
hyperplasia. There is no mention of IHC and no follow up was documented. Their much lower rate of 
false positives in comparison with the previous published studies and our current work may be related 
to the fact that their biopsies originate from a very limited number of pathologists from only two 
centres who have possibly been trained or are being influenced by the reference pathologist who 
confirmed or refuted their PC diagnoses for trial enrolment purposes.   
The observation that IHC had originally been performed on 7 (23%) of the 30 misdiagnosed cases of 
our study indicates that these had been identified as problematic. However, the result of this test was 
either misinterpreted or disregarded or in some cases relied upon despite its technical quality being 
suboptimal.  The crucial step of identifying a case as challenging did not prevent an over-call in a 
relatively high proportion of the discordant cases in this series. Specific training focusing on the 
interpretation of IHC results in the context of prostate cancer diagnosis could therefore have a major 
impact in improving the accuracy and reducing the false-positive rate in this field.  
If our percentage of false positives is applicable worldwide there are potentially large numbers of men 
with a misdiagnosis of prostate cancer every year. The majority are probably being labelled as low-
grade and nowadays it is reasonable to assume that a large proportion of these men are offered less 
aggressive forms of therapy or active surveillance. Nevertheless, the clinical, psychological and 
economic implications are still considerable.  
There has been a major decline in the percentage of false-positives compared to our previous study, 
from 7.5% to 2.2%. 8 That was based on a cohort of men diagnosed during the period 1990-1996 
whereas the median date of diagnosis of the current study is 2002. During this time interval, the main 
changes around prostate cancer histological reporting have been the wide implementation of IHC and 
subspecialisation in genitourinary pathology. A combination of both factors is probably responsible 
for the improvement. The percentage of false positives is lower in both papers published by the Johns 
Hopkins group at 1.1% and 1.2%. 7, 9 A possible explanation for this difference lies in the nature of the 
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cohorts. Theirs is based on cases referred for radical prostatectomy therefore there is selection bias 
towards more aggressive forms of cancer compared to our cohort formed of men who were treated 
conservatively. The much higher false-positive rate found by Bostwick et al  6 (20%) is hardly surprising 
taking into account that the original diagnosis was performed at a time when Gleason patterns 1 and 
2 were still viable entities. Most of these have subsequently been found to be benign lesions, mainly 
adenosis. 22 
In conclusion, this is the largest study on the histological false-positive diagnosis of prostate cancer 
with regards to biopsy numbers and the only one in which IHC was available as a diagnostic tool at the 
time of the misdiagnosis. We have shown the rate of false-positive cases to be 2.2% and have proved 
a very favourable outcome on long term follow up for this group, equivalent to that of Gleason 6 and 
much better than that of Gleason 7. We have identified adenosis as the most common explanation for 
the diagnostic discrepancy, in concordance with the previous studies on the subject. There has been 
a major reduction in the proportion of misdiagnoses in comparison with our previous study which we 
believe is the result of widespread implementation of IHC and specialist reporting in genitourinary 
pathology. However, 23% of the overcalls appear to be the consequence of misinterpretation of the 
IHC findings. In particular, it appears that in the context of a suspicious focus of glands with similar 
morphological features, a proportion of pathologists have treated each individual gland independently 
when the correct approach is to regard the entire population of glands as a whole at the time of 
evaluating IHC for basal cell markers. In our opinion specifically targeting interpretation of IHC in 
training courses and External Quality Assessment schemes could potentially lead to a further decrease 
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1. Adenosis. Core biopsy. H&E. Small tightly-packed acini with mild atypia. 
2. Adenosis. Core biopsy. 34BE12 immunostain performed originally demonstrates a 
discontinuous basal cell layer with occasional acini lacking basal cells in this section. 
3. Partial atrophy. Core biopsy. H&E. Disorganized acini of different size and shape with no 
significant atypia and no typical features of atrophy. 
4. Partial atrophy. Core biopsy. 34BE12 immunostain performed originally demonstrates a 
continuous basal cell layer. 
5. Adenosis. Core biopsy. H&E. Note fading staining. Dense area combining small and 
medium-sized acini with no significant atypia. 
6. Adenosis. Core biopsy. 34BE12 immunostain performed originally. Staining has failed 
and appears to highlight nuclei of luminal epithelial cells whilst it is completely negative 
in other areas. 
7. Sclerosing adenosis. TURP. H&E. Small round acini embedded in a richly cellular stroma. 
8. Seminal vesicle epithelium. Core biopsy. H&E. Marked nuclear atypia and 
intracytoplasmic pigment. 
 
 
